{
  "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
  "docSlug": "6d3545a6c010d7cb",
  "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
  "authorId": "GoldmanSachs",
  "authorName": "EyePoint Pharmaceuticals",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 8,
  "pageCount": 29,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "other",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide explains the mechanism of action (Vorolanib) and the delivery technology (Durasert E) for the product DURAVYU.",
  "elementsJson": [
    "headline_text",
    "process_diagram",
    "infographic",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/8",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-8",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Controlled release for at least 6 months",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-1d6c-779c-a61f-26a8af559313",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.03,
        "y": 0.4
      },
      "kind": "image",
      "text": "Mechanism of action diagram showing Vorolanib inhibiting VEGF receptors",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1025665b-bf91-405d-b039-afc3523a1f03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "image",
      "text": "Diagram of eye with insert",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c71c871-7016-40ef-8861-fcdeb2c09494",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.65,
        "y": 0.28
      },
      "kind": "list",
      "text": "Controlled release for at least 6 months; No delay; No fluctuation; No free-floating drug particles; No cold storage needed; No PEG or PLGA",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88f77b79-587b-472f-ba20-cd6c5d2031a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.35,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "Durasert E: Bioerodible, sustained IVT drug delivery",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e8ddc95-c479-4332-8c89-7ceeeb6631c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.03,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "Vorolanib: Patented and potent receptor tyrosine kinase inhibitor (TKI): selectively inhibits all VEGF signaling",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9c8ea47-e1b2-4e83-8bcd-78aa74a32311",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Bakri SJ, et al. PLoS One. 2024;19(6):e0304782. 2. Patel S, et al. Ophthalmol Sci. Sep-Oct 2024;4(5):100527. 3. Wykoff CC et al. J Vitreoretin Dis. Sep-Oct 2024;8(5):577-586.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "daef4263-01bb-422f-9a6b-92009fbe14ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.02,
        "y": 0.06
      },
      "kind": "title",
      "text": "DURAVYU™: Vorolanib in bioerodible Durasert E™",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4dcff0f3-a7fc-4dee-86b5-565050d2de18",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.35,
        "y": 0.18
      },
      "kind": "title",
      "text": "DURAVYU vorolanib intravitreal insert",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78bea56d-237d-4492-98be-3738ac8b9c29",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}